Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW B GENTRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1922072560
CMS profile
503391
Location
BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$414.03

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $414.03 15

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW B GENTRY

NPI 1922072560 · CMS profile ID 503391

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

BOZEMAN, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922072560?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922072560?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922072560?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDREW B GENTRY, NPI 1922072560, CMS profile ID 503391, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922072560?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $414.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $13.1811/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137553537 CMS
Boston Scientific Corporation $71.4311/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092547982 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.8510/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137553535 CMS
Olympus America Inc. $19.7710/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1108483526 CMS
Boston Scientific Corporation $53.6010/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092547980 CMS
ABBVIE INC. $15.9709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103786789 CMS
Janssen Biotech, Inc. $13.7108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078814492 CMS
Novo Nordisk Inc $18.3308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096649152 CMS
GENZYME CORPORATION $16.7608/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139962413 CMS
Boston Scientific Corporation $75.6207/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092547984 CMS
Intercept Pharmaceuticals, Inc. $21.0006/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113630532 CMS
Novo Nordisk Inc $18.5904/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097238255 CMS
Celgene Corporation $18.0003/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101138482 CMS
PFIZER INC. $19.6202/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131187611 CMS
PFIZER INC. $16.6001/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131116503 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $393.23 22
PY2020 $142.24 6
PY2021 $293.32 9
PY2022 $603.61 24
PY2023 $273.73 14
PY2024 $414.03 15
PY2025 $613.07 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $154,413.55 9
PY2022 Principal investigator $564,732.27 36
PY2021 Recipient $140.50 1
PY2021 Principal investigator $488,808.99 57
PY2020 Principal investigator $877,751.94 34
PY2019 Recipient $410.95 1
PY2019 Principal investigator $141,659.45 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $209.48 12/18/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673211
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,058.25 12/17/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-205 No dispute reported 06/30/2026 705397269
Principal investigator 1 PFIZER INC. $209.48 12/05/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677591
Principal investigator 1 PFIZER INC. $209.48 11/28/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678385
Principal investigator 1 PFIZER INC. $1,908.58 11/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670043
Principal investigator 1 PFIZER INC. $744.81 11/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670201
Principal investigator 1 PFIZER INC. $50.00 11/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674617
Principal investigator 1 PFIZER INC. $360.00 11/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678777
Principal investigator 1 PFIZER INC. $50.00 11/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671679363
Principal investigator 1 PFIZER INC. $209.48 10/23/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669461
Principal investigator 1 PFIZER INC. $720.00 10/16/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671165
Principal investigator 1 PFIZER INC. $100.00 10/16/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676277
Principal investigator 1 PFIZER INC. $360.00 10/16/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676305
Principal investigator 1 PFIZER INC. $50.00 10/16/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678449
Principal investigator 1 PFIZER INC. $2,334.50 10/09/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676205
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,250.00 10/08/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-205 No dispute reported 06/30/2026 705397263
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,665.00 10/08/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-205 No dispute reported 06/30/2026 705397265
Principal investigator 1 Ironwood Pharmaceuticals, Inc $4,150.00 10/08/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-205 No dispute reported 06/30/2026 705397267
Principal investigator 1 PFIZER INC. $2,656.87 10/02/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675305
Principal investigator 1 PFIZER INC. $209.48 09/18/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675565
Principal investigator 1 PFIZER INC. $2,427.61 09/11/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669821
Principal investigator 1 Eli Lilly and Company $5,950.00 09/05/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) No dispute reported 06/30/2026 654288969
Principal investigator 1 PFIZER INC. $50.00 08/28/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674435
Principal investigator 1 PFIZER INC. $631.92 08/28/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677915
Principal investigator 1 PFIZER INC. $2,524.20 08/14/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675361
Principal investigator 1 PFIZER INC. $2,866.35 07/24/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671643905
Principal investigator 1 PFIZER INC. $2,447.39 07/02/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671643573
Principal investigator 1 PFIZER INC. $2,427.61 06/26/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671643571
Principal investigator 1 Shire North American Group Inc $168.00 06/18/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637711931
Principal investigator 1 PFIZER INC. $4,572.41 05/29/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629187
Principal investigator 1 Shire North American Group Inc $815.00 05/21/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE No dispute reported 06/30/2026 637711423
Principal investigator 1 PFIZER INC. $2,676.65 05/15/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629221
Principal investigator 1 Eli Lilly and Company $20.00 05/09/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654288623
Principal investigator 1 PFIZER INC. $2,296.09 05/08/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629301
Principal investigator 1 Shire North American Group Inc $843.75 05/07/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637711135
Principal investigator 1 PFIZER INC. $4,056.85 05/01/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629297
Principal investigator 1 Eli Lilly and Company $5,950.00 04/23/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654289079
Principal investigator 1 PFIZER INC. $6,686.93 04/10/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628789
Principal investigator 1 PFIZER INC. $214.38 04/03/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628987
Principal investigator 1 Ironwood Pharmaceuticals, Inc $2,426.53 04/01/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-312 No dispute reported 06/30/2026 705397261
Principal investigator 1 Ironwood Pharmaceuticals, Inc $7,715.25 03/27/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-312 No dispute reported 06/30/2026 705397259
Principal investigator 1 PFIZER INC. $8,955.09 03/27/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628991
Principal investigator 1 Shire North American Group Inc $370.00 03/21/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637709685
Principal investigator 1 PFIZER INC. $593.51 03/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629201
Principal investigator 1 PFIZER INC. $5,306.73 03/13/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629291
Principal investigator 1 PFIZER INC. $3,002.48 03/04/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629203
Principal investigator 1 PFIZER INC. $214.38 03/04/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629269
Principal investigator 1 Ironwood Pharmaceuticals, Inc $60.00 02/22/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-312 No dispute reported 06/30/2026 705397253
Principal investigator 1 Ironwood Pharmaceuticals, Inc $240.00 02/22/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-312 No dispute reported 06/30/2026 705397255
Principal investigator 1 Ironwood Pharmaceuticals, Inc $252.00 02/22/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
MCP-103-312 No dispute reported 06/30/2026 705397257
Principal investigator 1 PFIZER INC. $2,839.56 02/20/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629141
Principal investigator 1 PFIZER INC. $5,775.72 02/13/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629175
Principal investigator 1 Shire North American Group Inc $18,295.00 02/12/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS
ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW No dispute reported 06/30/2026 637708611
Principal investigator 1 PFIZER INC. $214.38 02/06/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628725
Principal investigator 1 PFIZER INC. $8,323.17 02/04/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629367
Recipient Eli Lilly and Company $410.95 01/28/2019 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 654281469
Principal investigator 1 PFIZER INC. $10,945.10 01/16/2019 Non-covered Recipient Entity
BOZEMAN HEALTH DEACONESS HOSPITAL
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671629207